Charles River Laboratories Q2 2026 Earnings Beat Estimates; Stock Jumps 11.4%

What happened

Charles River Laboratories International, Inc. (CRL) reported second-quarter 2026 earnings that exceeded analyst estimates, according to an earnings call summary from Yahoo Finance. The company posted non-GAAP earnings per share of $3.02, beating expectations, and reported organic revenue growth of 0.1%, ending a nine-quarter streak of organic revenue declines as noted by Big Go Finance.

The company also raised its full-year 2026 guidance, now projecting flat to 1% organic revenue growth and non-GAAP EPS of $11.15 to $11.45, up $0.25 at the midpoint from its prior forecast, per MarketBeat. Shares rose 11.36% on the news, based on price data.

The filing

In its earnings release and conference call, Charles River Laboratories reported a sequential operating margin improvement of 420 basis points to 20.5% in Q2 2026, according to the Yahoo Finance summary. The company attributed the results to operational efficiencies and a stabilization in client demand, though specific drivers were not detailed in the provided sources.

The raised guidance reflects management's confidence in continued improvement, with the midpoint of the EPS range increasing by $0.25. Evercore ISI subsequently raised its price target on CRL to $300 from $260 while maintaining an Outperform rating, as reported by Investing.com (AU).

Market reaction

Shares of Charles River Laboratories closed up 11.36% on August 6, 2026, following the earnings announcement. The price move reflected investor optimism around the end of the organic revenue decline streak and the upward revision to guidance, as well as the analyst upgrade. No other material events were reported on the same day.